UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder-Reference-Cited by-同舟云学术

UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder

Published:2018-06-29 Issue:6 Volume:18 Page:740-748
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Hongkaew Yaowaluck,Medhasi Sadeep,Pasomsub Ekawat,Ngamsamut Nattawat,Puangpetch Apichaya,Vanwong Natchaya,Chamnanphon Monpat,Limsila Penkhae,Suthisisang Chuthamanee,Wilffert Bob,Sukasem Chonlaphat

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/s41397-018-0031-7.pdf

Reference38 articles.

1. Bethea TC, Sikich L. Early pharmacological treatment of autism: a rationale for developmental treatment. Biol Psychiatry. 2007;61:521–37.

2. Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol. 2008;18:157–78.

3. Haas M, Karcher K, Pandina GJ. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. J Child Adolesc Psychopharmacol. 2008;18:337–45.

4. Levine SZ, Kodesh A, Goldberg Y, Reichenberg A, Furukawa TA, Kolevzon A, et al. Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. Eur Psychiatry. 2016;32:16–20.

5. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2007;37:367–73.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of UGT1A1 polymorphism and baseline plasma bilirubin levels in predicting the risk of antipsychotic-induced dyslipidemia in schizophrenia patients;Schizophrenia;2024-05-17

2. Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism;Frontiers in Pharmacology;2024-02-05

3. Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications;Frontiers in Pharmacology;2024-02-05

4. Review of Pharmacogenomics of Psychiatric Comorbidities in Autism Spectrum Disorder;Pharmacogenomics;2023-09

5. Risperidone plasma concentrations are associated with hyperprolactinemia in autism spectrum disorder children: The impact of CYP2D6 polymorphisms;Research in Autism Spectrum Disorders;2022-08